【新冠病毒中和抗體|S2-特異性抗體】
|
|
|||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||
|
To support COVID-19 research, Sino Biological has developed a large collection of antibodies against different antigens of SARS-CoV-2. These antibodies can be used to detect and/or neutralize the virus in a variety of assays including ELISA, western blot, immunofluorescent staining, immunohistochemistry, SPR (Biacore and Octet), pseudovirus infection, and potentially in vivo animal studies. |
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
Specific and Neutralizing Antibodies against SARS-CoV-2 Spike |
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
Neutralization Activity Assay |
|||||||||||||||||||||||||||
|
Neutralizing antibodies can effectively inhibit the infection of SARS-CoV-2 Spike pseudovirus on ACE2 overexpression 293T cells. |
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
Competitive-ELISA Assay |
|||||||||||||||||||||||||||
|
Neutralizing ability was detected by SARS-CoV-2 Inhibitor Screening ELISA Kit (Catalog# KIT001) using competitive ELISA. |
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
Specificity Assay |
|||||||||||||||||||||||||||
|
These two anti-spike antibodies have been tested against all seven coronaviruses, and are shown to be specific to SARS-CoV-2 spike. The reactivity of the antibodies against the known coronaviruses is assessed in ELISA. The reactivity (OD450) is illustrated in the figures below. |
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
Antibody Against SARS-CoV-2 Spike S2 |
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
